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Purpose: Plan degradation resulting from compromises made to enhance delivery efficiency is an
important consideration for intensity modulated radiation therapy (IMRT) treatment plans. IMRT op-
timization and/or multileaf collimator (MLC) sequencing schemes can be modified to generate more
efficient treatment delivery, but the effect those modifications have on plan quality is often difficult to
quantify. In this work, the authors present a method for quantitative assessment of overall plan qual-
ity degradation due to tradeoffs between delivery efficiency and treatment plan quality, illustrated
using comparisons between plans developed allowing different numbers of intensity levels in IMRT
optimization and/or MLC sequencing for static segmental MLC IMRT plans.
Methods: A plan quality degradation method to evaluate delivery efficiency and plan quality trade-
offs was developed and used to assess planning for 14 prostate and 12 head and neck patients treated
with static IMRT. Plan quality was evaluated using a physician’s predetermined “quality degradation”
factors for relevant clinical plan metrics associated with the plan optimization strategy. Delivery ef-
ficiency and plan quality were assessed for a range of optimization and sequencing limitations. The
“optimal” (baseline) plan for each case was derived using a clinical cost function with an unlimited
number of intensity levels. These plans were sequenced with a clinical MLC leaf sequencer which
uses>100 segments, assuring delivered intensities to be within 1% of the optimized intensity pattern.
Each patient’s optimal plan was also sequenced limiting the number of intensity levels (20, 10, and 5),
and then separately optimized with these same numbers of intensity levels. Delivery time was mea-
sured for all plans, and direct evaluation of the tradeoffs between delivery time and plan degradation
was performed.
Results: When considering tradeoffs, the optimal number of intensity levels depends on the treatment
site and on the stage in the process at which the levels are limited. The cost of improved delivery
efficiency, in terms of plan quality degradation, increased as the number of intensity levels in the
sequencer or optimizer decreased. The degradation was more substantial for the head and neck cases
relative to the prostate cases, particularly when fewer than 20 intensity levels were used. Plan quality
degradation was less severe when the number of intensity levels was limited in the optimizer rather
than the sequencer.
Conclusions: Analysis of plan quality degradation allows for a quantitative assessment of the com-
promises in clinical plan quality as delivery efficiency is improved, in order to determine the optimal
delivery settings. The technique is based on physician-determined quality degradation factors and can
be extended to other clinical situations where investigation of various tradeoffs is warranted. © 2013
American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4808118]
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I. INTRODUCTION
Delivery efficiency is an important consideration in intensity
modulated radiation therapy (IMRT). The increased complex-
ity of IMRT plans leads to delivery times that can often be at
least twice as long as those for conventional plans.1 Delivery
efficiency depends both on the optimization and multileaf col-
limator (MLC) sequencing algorithms used in the treatment
planning process, as well as on the specific method of IMRT
delivery employed. Various more efficient optimization and
sequencing strategies, as well as direct aperture optimization
(DAO) and direct machine parameter optimization (DMPO)
techniques, have previously been investigated.2–15 These are
designed to reduce the number of monitor units (MUs) or
segments in a treatment plan, with the aim of reducing over-
all time and/or making the plans more robust to motion. Ef-
ficiency comparisons for different methods of static gantry
IMRT delivery have also been previously reported.16–19 The
focus on delivery efficiency has intensified with the recent
increased interest in rotational treatment delivery techniques
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such as volumetric modulated arc therapy (VMAT).14, 20–22
These techniques aim to reduce treatment time by delivering
radiation while the beam is rotating, and investigators have
reported on improved delivery efficiency for VMAT relative
to static gantry IMRT for several treatment sites.23–29
In general, more efficient delivery methods tend to reduce
the available degrees of freedom in the plan optimization.
This reduction can potentially degrade the plan which is fi-
nally delivered through compromises made during MLC se-
quencing or elsewhere in the planning process due to a re-
duction in the number of delivery degrees of freedom (e.g.,
limitations in intensity levels, number of segments, minimum
size of segments, etc.). As a result, the final plan quality may
be inferior to that of the optimal plan. However, the extent
of plan quality degradation is often unknown, since the dose
distribution from the optimal plan is not usually made avail-
able to the planner for review. Moreover, the effect of com-
promises made in plan quality on treatment outcome is not
easily measured. The tradeoff in delivery efficiency and plan
quality is, therefore, difficult to assess, and the ideal operating
point on the quality versus efficiency curve cannot be readily
determined. However, a method to clinically score plan qual-
ity degradation itself could be used to assess the tradeoff with
delivery efficiency.
Quantitative evaluation and comparison of plan quality, as
well as differences in plan quality which are achieved with
different IMRT optimization and sequencing methods, have
been investigated.18, 19, 30–32 These studies commonly compare
values of target dose homogeneity, maximum or average crit-
ical structure doses, or a penalty score from the cost func-
tion used in the optimization system. However, multiple plan
quality factors are difficult to combine into an overall mea-
sure of clinical plan quality without direct physician input.
Interpretation of the penalty cost is often complicated by the
different strategies which may be employed by different treat-
ment planners. In particular, expansions applied to contours
of targets and avoidance structures may differ, along with the
weights assigned to each objective in the overall cost func-
tion. Details of cost function implementations can also differ.
Achieving plan comparison scoring which incorporates all the
clinical concerns of the physician on a given case is even more
difficult, and all of these issues together make quantitative
comparison of different plans challenging.
In this work, we illustrate a method for evaluation of the
quality versus delivery efficiency tradeoffs which are often
imbedded in many IMRT and VMAT planning processes.
This method does not attempt to do overall plan quality scor-
ing, rather, it is intended only to characterize the clinical
tradeoffs which are made in an individual case as plan quality
is compromised to improve delivery efficiency. In this work
we demonstrate the technique by comparing the plan degra-
dation associated with intensity level quantization (typically
applied in IMRT plan sequencing or indirectly in DAO or
DMPO through the choice of allowable segments). In order to
provide a quantitative measure of overall plan quality degra-
dation, we employ physician-determined quality degradation
factors (QDFs) that relate all relevant plan metrics. Using this
method, clinical plan quality can be assessed quantitatively
and the tradeoff with delivery efficiency can be more thor-
oughly investigated.
Specifically, we use this method to evaluate the tradeoff
between delivery efficiency and clinical plan quality as the
number of intensity levels used in segmental MLC (SMLC)
delivery is varied for static gantry IMRT. The number of inten-
sity levels used in SMLC delivery correlates with the number
of segments needed to deliver the intensity profile for each
treatment field.19, 30 Treatment time increases as more seg-
ments are delivered due to the increased overall time for MLC
movement between segments, in addition to any per segment
treatment control system overhead that may exist, and may
increase due to use of more monitor units if smaller segments
are used to create the final field. However, using more in-
tensity levels in the optimizer may allow for a more optimal
plan to be achieved, and using more intensity levels in the se-
quencer may prevent further degradation of the optimal plan.
Previous investigators found that clinically acceptable plans
could be achieved with as few as five intensity levels.19, 30–32
However, this may not be the optimal number in terms of the
tradeoff between delivery efficiency and plan quality. Even
if a plan is of acceptable quality, it may be possible to im-
prove its quality without sacrificing much in terms of deliv-
ery efficiency. An understanding of how much plan quality
degradation occurs, for a given method of increasing delivery
efficiency, makes it possible to determine the optimal range
for the number of intensity levels. In this research, we use the
quality degradation factor method to investigate this tradeoff
for a series of clinical prostate and head and neck cases.
II. MATERIALS AND METHODS
II.A. Cases
Fourteen consecutive prostate cases and 12 consecutive
head and neck cases that were treated with IMRT in our de-
partment and met the prescription dose criteria were selected
for this retrospective analysis. The prescription dose for the
prostate cases was 77.7 Gy in 1.85 Gy fractions to the plan-
ning target volume (PTV), which consisted of the prostate and
some or all of the seminal vesicles plus a 5 mm expansion.
Organs at risk for these cases included the rectum, bladder,
penile bulb, and femoral heads. The prescription dose for the
head and neck cases was 70 Gy in 35 fractions for the high
dose PTV, while mid-dose PTV prescriptions were 59 or 63
Gy, and low dose PTV prescriptions were 56 or 59 Gy. Organs
at risk for these cases included the spinal cord, brainstem,
oral cavity, mandible, lips, larynx, parotids, submandibular
glands, esophagus, cochlea, brachial plexus, and pharyngeal
constrictors.
Treatment planning for all plans was performed with our
in-house-developed 3D planning system (UMPlan)33 and in-
verse planning system (UMOpt).34, 35 All cases were planned
for a Varian 21 EX linear accelerator with a 120 leaf multileaf
collimator (MLC). 6 MV beamlet IMRT was used for plan-
ning the head and neck cases and 16 MV beamlet IMRT (our
clinical standard) was used for the prostate cases. All plans
used 0.5 × 0.5 cm beamlets and the same beam directions
which had been used clinically: prostate plans all had seven
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fields, and the head/neck cases had nine fields (except for
one case each with eight and seven fields). The plans were
optimized with a simulated annealing-based optimization al-
gorithm using dose and dose-volume-based objectives cre-
ated with the previously described costlet functionality of the
optimization system.34 The optimized plans were sequenced
using an in-house-developed and previously described36 leaf
sequencer based on the Bortfeld method.37 All prostate
cases were optimized using one specific cost function. All
head/neck cases were optimized with the same cost function
except for differing mid and low dose target dose costlets as
required by the clinical prescription. One planner performed
the planning for all cases, and one physician evaluated all
plans. All optimizations were run until they converged. All
plans, including the baseline optimal plans (not limited in
the number of intensity levels), have been performed using
the standard clinical tools used within the department so all
can successfully pass the clinical QA criterion [using 1 mm
gradient-compensation,38 all detectors in the multi-ion cham-
ber IMRT QA device with dose >80% of the plan maximum
and with <10 cGy spread (across the individual ion cham-
ber) should be within ±4%, a much tighter criterion than the
often-used gamma of 3% and 3 mm for a composite delivery
at planned gantry angles]. This was confirmed with IMRT QA
measurements for an example prostate and example head and
neck for a subset of plans at multiple intensity levels utilizing
our 2D ionization chamber array (Scanditronix MatriXX) and
in-house developed analysis tools.
II.B. Treatment plan optimization and sequencing
The optimized plan from the clinically employed cost
function was used as the starting point for each case and was
termed the optimal or baseline plan. This plan was optimized
using an unlimited number of intensity levels in order to max-
imize the degrees of freedom available to the optimizer so it
could achieve the optimal solution. The optimal plan was se-
quenced with the clinical MLC sequencer,36 which uses 1%
intensity level steps and up to 250 segments per beam, in order
to assure delivered intensities are within 1% of the optimized
intensity pattern.
For the study comparisons, the compromises made by the
MLC sequencer and/or optimization system to limit the num-
ber of intensity levels (or segments) were separately evalu-
ated. To evaluate sequencer-related compromises, the opti-
mal plan was resequenced three additional times, using 20,
10, and 5 intensity levels (“Seq20,” “Seq10,” “Seq5,” respec-
tively). To evaluate making the same intensity level compro-
mises, except within the optimizer, the optimal plan was fur-
ther optimized three times, with 20, 10, and 5 intensity levels
available in the optimizer (“Opt20,” “Opt10,” “Opt5,” respec-
tively). For these optimizations, the beamlet intensities from
the optimal plan were initially rounded to the nearest fixed in-
tensity level, and then the optimization was restarted using the
same cost function and run until the penalty cost converged.
The newly optimized plans were then sequenced using the
same number of intensity levels in the sequencer as were used
in the optimizer.
II.C. Delivery efficiency and quality degradation factor
Sequencer and optimizer-related compromises were eval-
uated by assessing the tradeoffs between delivery time and
clinical plan quality for the reduced intensity level plans com-
pared to the optimal plan. Total beam delivery time was de-
termined by delivering each plan on a Varian 21iX equipped
with a Millennium MLC and summing the beam-on time for
each beam.
Clinical plan quality was assessed using physician-
assigned clinically relevant plan metrics. These metrics were
determined before the experiment and then used as a means
to quantify the degradation in clinical plan quality for the re-
duced intensity level plans relative to the optimal plan. Plan
evaluation metrics included D99 (the dose covering 99% of
the highest dose volume), D1 (the mean dose to the maximum
1% of the volume), V75 (volume of the 75% isodose surface),
Dmean (the mean dose), and others.
To have a systematic measure of plan degradation for each
site, a physician assigned the relative importance of degrada-
tion that might occur in each normal tissue metric for each
target and critical structure. The goal of these assignments
was for the physician to describe the relative importance of
change in each metric as it affects the physician’s plan eval-
uation. The overall quality degradation score is then directly
relatable to changes in the clinical metrics they have chosen
to evaluate when comparing rival plans. Defining a method
which gives a single overall quality degradation score is very
important, since plan quality compromises usually affect both
target coverage and normal tissue doses, and comparison of
dose volume histograms alone is unable to quantify the vary-
ing amounts of improvement and/or degradation that occur
to the various structures with a given technique change. The
QDF for a structure can be defined by pairwise comparison
of the importance of a change in one metric with respect
to another. Typically we have defined QDFs with respect to
changes in the primary target metric, using a QDF of 1 for a
1 Gy decrease in the target dose metric value. For example, if
a 1 Gy decrease in the minimum target dose is just as impor-
tant as a 10 Gy increase in the mean dose metric for a normal
tissue, then the QDF for the normal tissue would be 0.1/Gy,
since 0.1/Gy × 10 Gy gives the same value as the 1 Gy change
in target dose.
For this work, the QDFs for the prostate and head/neck
cases were defined by a single physician before the experi-
ment was performed. For all the experiments, a QDF of 1.0
was assigned to a 1 Gy decrease in the main target metric,
D99 (the dose covering 99% of the highest dose PTV volume).
All other QDFs were assigned by the physician based on the
relative importance of changes in each metric according to
the physician’s clinical judgment, using comparison of each
metric (one by one) to the 1 Gy decrease in the target metric
(as described above). For a given plan, each relevant metric
change from that achieved by the optimal plan was multiplied
by its corresponding QDF, and the sum of those products was
called the plan quality degradation (QD). The QD is a rela-
tive measure of degradation for plans evaluated according to
the chosen metrics. The comparisons of QDs for two different
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TABLE I. Physician-assigned QDFs for prostate cases per Gy or % as indi-
cated in the table. A QDF of 1 represents a 1 Gy decrease in the D99 coverage
of the PTV.
PTV Rectum BladderStructure Bulb Femurs
Parameter D99 D1 D1 V70 V50 D1 V75 V50 Mean D1
QDF 1 1 1 0.2 0.2 0.5 0.1 0.1 0.1 1 if >45 Gy
Units Gy Gy Gy % % Gy % % Gy Gy
sites or for very different evaluation schemes are not expected
to be directly informative, since the QD is only intended to
quantify plan degradation for a given site, set of clinical met-
rics, and physician evaluation scheme.
Physician-assigned QDFs are listed in Table I for the
prostate cases. This table illustrates that deviations for the
rectum were considered more important for plan quality, by
this particular physician, than those for the bladder. For
head and neck cases, a QDF of 1.0 was assigned to the pri-
mary target metric, D99, for the 70 Gy PTV, and smaller
QDFs were assigned for coverage of the lower dose PTVs
(Table II). The cord structures were defined to be the most
important normal structures, followed by the brachial plexus
and cochlea. Note that the QDF does not define the impor-
tance of the structure as a whole, it only defines the impor-
tance of changes to that particular metric for that structure.
It is of course possible to evaluate and include multiple dosi-
metric (or other) metrics for a given structure, each with their
own QDF.
For each case, the beam-on time was measured for the
optimal plan and all six reduced intensity level plans. The
plan quality degradation relative to the optimal plan was
also calculated for these six plans. The clinical plan qual-




The isodose distribution from an optimal plan for a typical
prostate case (optimized with an unlimited number of inten-
sity levels in the optimizer) is shown in Fig. 1(a) to illustrate
the quality of the optimal plans. The plan is highly conformal
with the 77 Gy isodose line nearly completely covering the
PTV, little dose above 83 Gy, and steep dose gradients in the
direction of the rectum and bladder. Figures 1(b)–1(d) show
the dose difference as the number of intensity levels used in
the sequencer is reduced. Figures 1(e)–1(g) show the dose
differences which result when the plan is reoptimized (in the
optimizer) using smaller numbers of intensity levels. In both
cases, dose differences from the optimal plan become more
substantial as fewer intensity levels are used, as one would
expect. The maximum differences in both cases are typically
less than 2 Gy for 20 and 10 intensity levels but exceed 3–
4 Gy when only 5 intensity levels are used. However, when
the changes are made in the sequencer alone, the dose dif-
ferences seemingly are randomly spread around, leading to a
larger decrease in the PTV dose homogeneity [as evidenced
by the increased hot and cold regions in Fig. 1(d)]. This may
also lead to increased maximum doses in organs at risk if ran-
dom beamlet increases occur in the hottest regions.
Clinical DVH criteria and beam-on time for this example
case are listed in Table III. Data for the femoral heads and pe-
nile bulb are not listed as they remained essentially unchanged
regardless of the number of intensity levels used. The data in-
dicate that most of the plan quality degradation comes from
the PTV D99 and D1 values (due to their high priorities in the
cost function and importance to the physician’s evaluation),
with bigger deviations for sequencer-reduced intensity levels.
The total plan quality degradation for each method of reduc-
ing intensity levels is plotted versus beam-on times in Fig. 2.
A quality degradation of 1 is equivalent to a 1 Gy decrease
in D99 for the PTV. The plot demonstrates that the tradeoff
TABLE II. Physician-assigned QDFs for head and neck cases. A QDF of 1 represents a 1 Gy decrease in the D99 coverage of the high dose (70 Gy) PTV. Note
that for serial critical structures, the penalty was only applied if the D1 value exceeded the planned dose limit for the structure.
PTVhigh PTVmid PTVlowStructure
Parameter D99 D1 D99 D1 D99 D1
QDF 1 1 0.5 1 0.3 1
Units Gy Gy Gy Gy Gy Gy
Structure Parotids Oral cavity Larynx Esophagus Submandibular glands Lips Constrictors
Parameter Dmean Dmean Dmean Dmean Dmean Dmean Dmean
QDF 0.1 0.1 0.2 0.1 0.1 0.1 0.1
Units Gy Gy Gy Gy Gy Gy Gy
Structure Cord Cord + 5 Mandible Brachial plexus Cochlea
Parameter D1 > 45 Gy D1 > 50 Gy D1 > 70 Gy D1 > 60 Gy D1 > 40 Gy
QDF 10 10 1 3 3
Units Gy Gy Gy Gy Gy
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FIG. 1. Isodose distributions from the optimal plan for a prostate case (a) along with dose difference distributions (b)–(h) between reduced intensity level plans
and the optimal plan. The number of intensity levels used was reduced to 20, 10, and 5 in the sequencer (b)–(d) and in the optimizer (e)–(g). Dose differences
are shown in absolute dose (Gy).
in plan quality degradation versus beam-on time is relatively
small in going from an unlimited number of intensities to 20
intensity levels, but that the degradation then becomes larger
with each successive reduction in number of intensity levels.
This graph can be interpreted as illustrating that choosing a
plan which has been limited to only five intensity levels in the
MLC sequencer has been degraded (in total) as much as de-
creasing the minimum dose to D99 by 4 Gy, while if that lim-
itation of intensity levels had been made in the optimizer, the
total degradation would have been halved, to only the equiva-
lent of a 2 Gy compromise in D99. Perhaps most interestingly,
these compromises may be unknown to the planner if the sys-
tem is always used with the five intensity level choice.
Plan quality degradation versus beam-on time for all 14
prostate cases is plotted in Fig. 3. In all cases, plan quality
degradation increases in the same way as the number of in-
tensity levels decreases, and more or less degrades approxi-
mately the same amount as the number of intensity levels is
decreased.
III.B. Head and neck cases
The isodose distribution from the optimal plan for a typ-
ical head and neck case is shown in Fig. 4. Plan complex-
ity for the head and neck cases is clearly greater than that
for prostate cases. The minimum dose target coverage for all
three PTVs is adequate, but the hotspots in the PTV70 target
are larger than seen for most prostate cases. The dose differ-
ence plots in Fig. 4 for the Opt20, Opt10, Opt5 and Seq20,
Seq10, Seq5 plans indicate that it is also more difficult to
maintain the same plan quality as the number of intensity
levels is reduced, particularly when they are reduced in the
sequencer. Maximum target doses and PTV coverage notice-
ably suffer when ten or five intensity levels are used in the se-
quencer. Due to the often seemingly random nature of beamlet
intensity modifications, the dose to some critical structures in-
creases while the dose to others decreases. This is shown in
Table IV, which lists the pertinent dose information as well
as the beam-on times for all plans. The changes are more
controlled when the number of intensity levels is reduced in
the optimizer, although plan quality clearly suffers with this
method as well.
A plot of plan quality degradation versus beam on time for
this example case is shown in Fig. 5. A plan quality degra-
dation of 1.0 is equivalent to a decrease in D99 for PTV70
of 1 Gy. It is again evident that plan quality degradation is
more substantial when reducing the number of intensity lev-
els in the sequencer compared to reducing it in the optimizer.
However, it is also clear that the degradation values are larger
TABLE III. Clinical DVH criteria for the plans shown in Fig. 1. The values for the optimal plan are shown, while the differences from that optimal plan metric
are shown for the sequencer (Seq) and optimization (Opt) defined intensity level plans.
Structure Criteria Optimal value Seq 20 Seq 10 Seq 5 Opt 20 Opt 10 Opt 5
PTV D99 77.3 0 − 0.5 − 1.6 − 0.1 − 0.2 − 0.7
D1 83.3 +0.2 +0.2 +1.8 0 +0.1 +0.7
Rectum D1 77.9 +0.1 +0.3 +0.3 0 0 +0.5
V70 11.9 0 +0.1 0 0 +0.1 − 0.3
V50 19.9 0 +0.1 0 0 +0.1 − 0.1
Bladder D1 74.5 − 0.1 +0.1 +0.2 − 0.1 +0.1 +0.6
V75 2.8 0 0 0 0 0 +0.1
V50 6.6 0 0 +0.1 0 0 +0.1
Time Minutes 5.00 − 1.32 − 1.77 − 2.20 − 1.38 − 1.78 − 2.23
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FIG. 2. Plan quality degradation versus beam-on time for a sample prostate
case as the number of intensity levels is reduced in either the sequencer
(dashed red line) or the optimizer (solid blue line). Labels on the graph show
the number of intensity levels used.
for this case compared to the prostate case. The beam-on
times are also greater, meaning more time savings are pos-
sible relative to the optimal plan. This is also shown in Fig. 6,
where the plan quality degradation is plotted versus beam-on
time for all 12 cases. For each case, the tradeoff in plan qual-
ity when reducing from unlimited intensity levels to 20 levels
is relatively small, but the degradation increases substantially
when the number of intensity levels is changed from 20 to 10,
and even more from 10 levels to 5.
III.C. Overall analysis
The average tradeoff (and standard deviation, shown by
the error bars) for each successive intensity level reduction
in the sequencer and in the optimizer, for both prostate and
head/neck cases, is plotted in Fig. 7. For both prostate situa-
tions, the average tradeoff in going from an unlimited number
of intensity levels in the optimizer down to 20 levels degrades
the plan less than 0.1 Gy (in D99) (per minute of decreased de-
FIG. 3. Plan quality degradation versus beam-on time for all prostate cases
as the number of intensity levels is reduced in either the sequencer (dashed
red lines) or the optimizer (solid blue lines).
livery time) for prostate and 0.2 Gy (in D99 of PTV70)/(min
saved) for the H/N cases. As the number of intensity levels
is further decreased from 20 to 10 and then from 10 to 5, the
prostate tradeoff QDF averages go from 1 to 5.9 Gy (in D99
per minute saved) for prostate, and from 1.8 to 10.5 Gy/(min
saved) for the H/N cases. The quality degradation tradeoffs
are substantially larger when the number of intensity levels is
reduced in the sequencing step alone, especially for the first
two intensity level reductions. This last decrease to five in-
tensity levels degrades prostate plans by a total degradation
which is equal to underdosing the dosimetric prescription by
5.2 Gy, on average, a substantial degradation (according to the
evaluation scheme developed for these cases). For the H/N
cases, cutting the number of intensities from ten to five can
cause quality degradation of as much as 15 Gy/min saved.
Though there are differences that depend on the type of case,
the quality degradation per minute saved is within a factor
of 2 for the two very different types of cases, so it is possible
this parameter is reasonably consistent and independent of the
type of case.
FIG. 4. Isodose distributions from optimal plan (a) for a head and neck case along with dose difference distributions (b)–(h) between reduced intensity level
plans and the optimal plan. The intensity levels were reduced to 20, 10, and 5 in the sequencer (b)–(d) and in the optimizer (e)–(g). Dose differences are shown
in absolute dose (Gy).
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TABLE IV. Clinical DVH criteria for the plans shown in Fig. 4. The serial critical structures are not listed because the dose limits were not exceeded for any of
the plans. The value for the optimal plan is shown, while the differences from that optimal plan metric are shown for the sequencer (Seq) and optimization (Opt)
defined intensity level plans.
Structure Criteria Optimal value Seq 20 Seq 10 Seq 5 Opt 20 Opt 10 Opt 5
PTVhigh D99 68.2 − 0.3 − 1.5 − 4.4 − 0.1 − 1.0 − 2.5
D1 74.5 0.6 2.8 4.5 0.1 0.8 2.6
PTVmid D99 57.7 − 0.4 − 1.6 − 3.1 − 0.2 − 0.7 − 2.0
D1 70.5 +0.7 +2.6 +3.6 +0.2 +0.7 +1.6
PTVlow D99 54.6 − 0.5 − 1.8 − 4.2 − 0.1 − 0.6 − 2.3
D1 59.8 +0.9 +1.4 +5.5 +0.2 +0.5 +2.6
Right parotid Dmean 36 +0.4 − 1.4 − 1.7 +0.1 +0.8 +0.9
Left parotid Dmean 21.3 − 0.1 +0.1 − 0.8 +0.7 − 0.2 +2.0
Oral cavity Dmean 29.9 − 0.1 +0.1 +0.1 − 0.2 +1.0 +2.4
Esophagus Dmean 20.2 +0.2 0 − 1.1 +0.2 +0.1 +0.9
Left submandibular Dmean 45.5 +0.1 − 1.1 +3.1 +0.1 +1.5 +2.7
Constrictors Dmean 44.6 +0.1 − 2.2 − 0.5 − 0.1 +0.6 +2.7
Time Minutes 9.90 − 4.80 − 6.15 − 6.94 − 4.82 − 5.89 − 6.72
IV. DISCUSSION
In this work the tradeoff between clinical plan quality
and delivery efficiency has been assessed for IMRT prostate
and head and neck plans using the plan quality degradation
method. The method has been demonstrated using example
comparisons for step and shoot IMRT delivery based on the
use of different numbers of intensity levels in the sequencer
or the optimizer.
The fact that plans degrade as the number of intensity lev-
els used is decreased has been demonstrated by many authors,
as has the fact that plans become less complex and faster
to deliver as the number of intensity levels decrease. In this
paper, however, the plan quality degradation is defined by a
single clearly defined clinically relevant metric tuned to the
specific goals of a physician for that patient, so that the com-
promises made with various optimization and delivery deci-
sions have a specific clinical importance. For example, for the
data in Fig. 7, choosing to change the number of intensity lev-
els used in the sequencer for a head/neck case from optimal
to 10 will cause a plan degradation value of 4/min of delivery
FIG. 5. Plan quality degradation versus beam-on time for sample head and
neck case as the number of intensity levels is reduced in either the sequencer
(dashed red line) or the optimizer (solid blue line).
time: saving 1 min of delivery time will result in plan degra-
dation equivalent to a decrease of 4 Gy in the minimum dose
to the target volume. The physician then decides if saving
1 min of delivery time is worth a minimum target dose value
4 Gy lower than the desired value. Rarely have plan efficiency
delivery compromises been quantified so clearly to the physi-
cian who must make the tradeoff decision.
Plan quality degradation, relative to the optimal plan, was
much more substantial (by a factor of 2 or more) when the
number of intensity levels was reduced in the sequencer than
when the optimizer was used with that same limited number
of intensity levels. This is not surprising, since some of the
loss of plan quality can be avoided when optimization based
on the plan’s cost function is applied with the remaining inten-
sity levels. The plan quality degradation was also more sub-
stantial for head and neck cases than for prostate cases with
the same reductions in number of intensity levels. This is also
expected, since the head and neck plans were more complex,
with more PTV volumes and critical structures. However, the
beam-on times were longer for the head and neck cases, so
FIG. 6. Plan quality degradation versus beam-on time for all head and neck
cases as the number of intensity levels is reduced in either the sequencer
(dashed red lines) or the optimizer (solid blue line).
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FIG. 7. Average additional plan quality degradations for each successive
decrease in number of intensity levels (in the sequencer and the optimizer)
for prostate and head and neck cases are shown in terms of degradation per
minute. Error bars correspond to the standard deviations.
greater time savings (relative to the optimal plans) could be
achieved with the head and neck plans when the number of in-
tensity levels was reduced. Therefore, tradeoffs in plan quality
versus delivery efficiency were more similar for the two treat-
ment sites than one might initially expect, and may in fact be
close enough that the quality degradation per minute saved
may be a relatively consistent parameter for different types of
cases.
The tradeoff plots can be used as a guide to determine
the optimal number of intensity levels for these IMRT cases.
This requires a determination of the acceptable plan quality
degradation (per minute saved) for a particular treatment site.
For example, if the acceptable cutoff was determined to be
2 QDF/min (i.e., we are willing to allow a decrease in tar-
get minimum coverage of 2 Gy/min of delivery time saved),
then the ideal operating point on the tradeoff curve would
be approximately 10 intensity levels in the optimizer for the
prostate cases and closer to 20 intensity levels for the head and
neck cases. All but one of the prostate cases meet this cutoff
for 10 intensity levels while only 7 of the 12 head/neck cases
meet this cutoff for 10 intensity levels. The optimal number of
intensity levels in the sequencer alone would be 20 for both
sites.
Understanding the kinds of plan degradation that occur due
to standard planning system decisions may be important in
many circumstances. For example, if an institution’s standard
planning technique were to limit the number of intensity lev-
els to five, then the planner and physician may never know
that the planning/optimization system has this degradation in-
corporated into its plans, and that the plans could potentially
be significantly better with different parameter choices for the
number of intensity levels used.
The plan quality degradation method described here can be
used with any planning system and/or optimization method
and/or changing planning technique, since it depends only
on the clinical metrics chosen for plan evaluation and on the
physician’s choices about comparative importance of the var-
ious metrics. Each physician may in fact have their own set
of QDFs for a given type of case, since the goal of the QDF
choices is to quantify the physician’s decisions about impor-
tance of various metrics as they evaluate plans. This technique
is used here simply to help quantify the delivery efficiency
versus plan quality tradeoffs, rather than the more general and
difficult comparisons between very different types of plans.
Given the limited goal for the quality degradation (i.e., deter-
mining the appropriate delivery efficiency versus plan quality
tradeoff for a given case or cases), using this method should
not introduce additional errors in the plan evaluation process,
since it does not replace the clinical evaluation process, it sim-
ply helps the physician quantify the specific efficiency versus
quality tradeoffs which might be available.
The physician-assigned QDFs (units of plan quality degra-
dation) used in this study were considered to be linear for the
sake of simplicity, though other behavior is certainly possible.
For example, small changes in degradation may vary linearly
with importance, but degradation that passes some threshold
may become much more important (i.e., different than linear).
For example, the QDF for a decrease in D99 of the PTV may
get much larger (>1 QDF/Gy) when this value falls below
95% of the prescription dose. An increase in the mean parotid
dose of 1 Gy may also have a greater impact on plan quality
when the dose increases above 26 Gy. If these step-wise in-
creases in plan quality degradation were incorporated into the
analysis, the overall plan quality degradations would typically
increase, particularly for more modulated plans. This would
impact the degradation versus efficiency tradeoffs and could
affect the determined optimal number of intensity levels.
It is important to note that the efficiency versus plan qual-
ity tradeoff depends on the machine and the specific type of
IMRT delivery being used. Our results come from a modi-
fied Bortfeld sliding window SMLC delivery using a Varian
2100 iX linear accelerator with a 120 leaf MLC. For this ma-
chine and delivery method, the increase in delivery time with
increasing number of segments is due almost entirely to leaf
travel time between successive segments, as there is very lit-
tle additional per segment overhead, and in these results there
was little variation in the number of MUs with changes in the
number of intensity levels. For delivery systems that add addi-
tional overhead for each segment, the tradeoff curve would be
different, leading to a different choice of the optimal tradeoff
between treatment time and plan quality.
The plan quality versus delivery efficiency tradeoff also de-
pends on the treatment modality. The cost of improved plan
quality, in terms of beam delivery time, depends on the de-
grees of freedom available and the plan complexity. For 3D-
CRT treatments, the beam-on delivery time component comes
only from the number of MUs, which can increase with the
addition of subfields. The ideal number of fields is likely to
be higher for more complex treatment sites where adding
fields may have a more substantial impact on plan quality.
For IMRT treatments, the number of degrees of freedom is
typically large, and there may be the potential to decrease
treatment times without substantial degradation of plan qual-
ity, particularly for less complex treatment geometries. On the
other hand, improvements in plan quality may also be possible
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without greatly increasing delivery time for IMRT plans. Plan
quality for DAO and DMPO plans is dependent on the number
of segments allowed as well as other details of the algorithms
and implementation. For VMAT plans, the delivery time de-
pends on gantry speed, dose rate, MLC leaf speed and dis-
tances to be traveled, and number of MUs. These factors are
determined by plan complexity, and efficiency improvements
may or may not substantially degrade plan quality. The qual-
ity versus delivery time tradeoff for VMAT (or versus fixed
field IMRT) is another prime candidate for evaluation using
the plan degradation method described in this work, since the
method does not depend on any details of the optimization,
and it only relates the various clinical metrics with which the
plan is evaluated. Though some VMAT implementations have
a very limited number of user-adjustable parameters, the same
kind of quality compromises which occur in IMRT sequenc-
ing are often incorporated into the VMAT methods. Further
study of VMAT-related tradeoff issues is the subject of on-
going research.
The key for any treatment modality is to determine the po-
sition of the current operating point on the degradation ver-
sus efficiency tradeoff curve in relation to the ideal operat-
ing point. This is also true for making comparisons between
different treatment techniques. Without detailed study (for a
given technique, or for comparisons of different techniques),
this position on the curve may not be known. The clinically
defined plan quality degradation metrics can be used for many
techniques, and with care across different techniques, to help
delineate the quality versus delivery efficiency tradeoffs and
to determine the optimal techniques and parameters to be
used for planning and delivery for a given treatment site and
protocol.
V. CONCLUSIONS
This work has investigated the use of the plan quality
degradation method to evaluate the tradeoff between plan
quality and treatment delivery efficiency using example ex-
periments with sets of prostate and head and neck IMRT cases
using the SMLC delivery technique with varying numbers of
intensity levels. The method allows for a quantitative assess-
ment of the compromises in clinical plan quality as delivery
efficiency is changed, in order to determine the optimal de-
livery settings. The plan quality degradation method is based
on physician-assigned plan quality degradation factors and
does not depend on the details of the plan optimization system
used, so it may easily be extended to other treatment modali-
ties, sites, and comparisons.
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